MorphoSys initiates Phase III trial of MOR208 and bendamustine for DLBCL

German biotechnology firm MorphoSys has initiated patient enrolment for the Phase III part of the Phase II/III B-MIND clinical trial of MOR208 and bendamustine combination to treat diffuse large B-cell lymphoma (DLBCL).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news